Psychedelics for treatment resistant depression: are they game changers?
Expert Opinion on Pharmacotherapy – November 10, 2023
Source: OpenAlex
Summary
Psychedelic therapy is creating a paradigm shift in Medicine for Treatment-resistant depression. Psilocybin, a potent alkaloid, shows extraordinary antidepressant promise. This compound, often from chemical synthesis, rapidly influences neurotransmitter receptors, with some individuals experiencing benefits sustained for at least 3 months. This could transform Psychiatry, offering psychotherapists a novel approach to severe Depression and potentially easing its economic burden. Ongoing drug studies are exploring these powerful compounds, providing hope where traditional treatments often fail.
Abstract
Psychedelic therapy has created a paradigm shift in the treatment of TRD, as it can maximize therapeutic benefits and minimize potential risks. Psilocybin holds promise as a potential game-changer in the treatment of TRD, with initial evidence suggesting a rapid antidepressant effect sustained for some responders for at least 3 months. Nevertheless, further adequately powered, double-blind, comparator-controlled trials are required to explore and clarify the mechanisms of action and long-term effects of psychedelics in TRD. Psychedelics also hold promise for other psychiatric conditions, such as bipolar depression and post-traumatic stress disorder.